Clearmind Medicine announced the closing of its United States-only public offering with gross proceeds to the company of approximately $2.25M. The offering consisted of 7.5M common shares that were sold at 30c. Conmed expects to use the net proceeds from the offering for general corporate purposes. Aegis Capital acted as exclusive placement agent for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CNMD:
- Conmed price target raised to $145 from $128 at Piper Sandler
- Conmed price target raised to $141 from $131 at KeyBanc
- Conmed raises FY23 EPS view $3.40-$3.55 from $3.30-$3.50, consensus $3.42
- Conmed reports Q2 adjusted EPS 83c, consensus 79c
- CNMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
